Xcout Intel
Alixia, Inc.
Alixia, Inc. is a biotechnology company that develops therapeutics targeting tumor ecosystems to address cancer drug resistance and complex, chronic diseases. The company utilizes a research platform integrating biology, biophysics, computational chemistry, and clinical input to discover lead compounds that disrupt metabolic and inflammatory triggers within the tumor microenvironment.
Subscribe to see Alixia, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alixia, Inc. at a glance
Alixia, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $1.8M in July 2024. Xcout tracks 2 named people at Alixia, Inc., including Helen Chen (Co-founder & Co-CEO).
Alixia, Inc. leadership
- Helen ChenCo-founder & Co-CEO
- Olof MollstedtCo-founder & Co-CEO
Alixia, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $1.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Alixia, Inc. competitors
A few of Alixia, Inc.'s closest competitors — see the full list of competitors and alternatives →
Atavistik Bio is a U.S. biotechnology company developing small-molecule medicines by targeting allosteric sites and metabolite-regulated biology, using its chemoproteomics and drug-discovery platform. Its programs are aimed at treating cancer and other serious diseases.
Alivexis, Inc. is a technology-driven drug discovery enterprise utilizing advanced pharmaceutical platforms with operational foundations in Japan and the United States. Its headquarters is located in Minato-ku, Tokyo, Japan.
Axiom Bio is a biotechnology company that develops AI-driven predictive models and translational intelligence tools to assess drug toxicity and minimize clinical trial failures in drug discovery.
Oncodesign Precision Medicine is a biopharmaceutical company that develops innovative therapeutic and diagnostic solutions targeting treatment resistance, metastasis, and diseases such as oncology, inflammatory bowel disease, and Parkinson's disease. Utilizing proprietary technologies like OncoSNIPER, Nanocyclix, and PROMETHE, the company advances first-in-class and best-in-class precision medicine programs to serve patients, clinicians, and pharmaceutical partners.
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Convexia is a biotechnology research company headquartered in San Francisco, California, United States. It utilizes an end-to-end AI stack to quickly find and acquire early-stage drugs, replacing traditional manual diligence processes with fast execution.
Get Alixia, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alixia, Inc. in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access